Scientific evidence

The science behind INNOVATIO-ND2

INNOVATIO-ND2 is a predictive test based on protein biomarkers that uses the PromarkerD™ algorithm, discovered by Proteomics International scientists and validated in more than 4,000 patients.

Discovery study

The original study by Drs. Timothy Davis and Richard Lipscombe (Proteomics International) that identified the biomarkers in the PromarkerD algorithm.

Download PDF

Validation in the CANVAS study

The largest validation study, with Janssen, confirming PromarkerD's ability to identify and stratify the risk of diabetic kidney disease (Peters et al., Journal of Clinical Medicine, 2020).

Download PDF

Technical equivalence: mass spectrometry vs. ELISA

Cross-validation showing that the INNOVATIO-ND2 ELISA is clinically equivalent to the original platform.

Download PDF

Economic model (ADA 2021)

Poster presented at ADA 2021 on potential savings for the U.S. health system from identifying at-risk patients early and keeping them off dialysis.

Download PDF

Response to SGLT2i (canagliflozin)

In this 2021 poster, SGLT2 inhibitors such as canagliflozin significantly lowered PromarkerD-measured risk versus placebo over 3 years.

Download PDF
Learn more

PromarkerD

INNOVATIO-ND2 is known as PromarkerD™ in other countries.

promarkerd.com →